Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial-Reference-Cited by-同舟云学术

Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial

Published:2017-02-21 Issue:7 Volume:116 Page:859-863
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Pinder S E, ,Campbell A F,Bartlett J M S,Marshall A,Allen D,Falzon M,Dunn J A,Makris A,Hughes-Davies L,Stein R C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201728.pdf

Reference17 articles.

1. Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M (2009) Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 20: 1948–1952.

2. Bartlett JM, Starczynski J, Atkey N, Kay E, O'Grady A, Gandy M, Ibrahim M, Jasani B, Ellis IO, Pinder SE, Walker RA (2011a) HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol 64 (8): 649–653.

3. Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D (2011b) Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 29: 1531–1538.

4. Bartlett J, Canney P, Campbell A, Cameron D, Donovan J, Dunn J, Earl H, Francis A, Hall P, Harmer V, Higgins H, Hillier L, Hulme C, Hughes-Davies L, Makris A, Morgan A, Mccabe C, Pinder S, Poole C, Rea D, Stallard N, Stein R (2013) Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial. Clin Oncol (R Coll Radiol) 25 (2): 109–116.

5. Bartlett JM, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, Sobol MS, Hall PS, Poole CJ, Cameron DA, Earl HM, Rea DW, Macpherson IR, Canney P, Francis A, McCabe C, Pinder SE, Hughes-Davies L, Makris A, Stein RC OPTIMA TMG (2016) Comparing breast cancer multiparameter tests in the OPTIMA Prelim Trial: no test is more equal than the others. J Natl Cancer Inst 108 (9): pii: djw050.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concordance of RT-qPCR with immunohistochemistry and its beneficial role in breast cancer subtyping;Medicine;2023-09-22

2. Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer;Bioscience Reports;2022-01

3. A Novel Data Analytics-derived Metric (Nearest Cluster Distance) Is Easily Implemented in Routine Practice and Correctly Identifies Breast Cancer Cases for Quality Review;Journal of Pathology Informatics;2022

4. Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review;Clinical Genetics;2020-12-28

5. Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience;Cancer Cell International;2019-10-11